iCAD Highlights Promising Clinical Data Demonstrating Ability to Reduce Breast Interval Cancer Rates and Decrease Recall Rates at ECR 2024; Showcases Additional Platform Offerings
Stock Information for iCad Inc.
Loading
Please wait while we load your information from QuoteMedia.